Montevisin, eye drops 0.05%, 10 ml

Alpha-adrenomimetic.

Alpha-adrenomimetic, imidazole derivative, has vasoconstrictor and anticongestive effect.

Vasoconstrictor effect without secondary reactive hyperemia develops within a few minutes and lasts 4-8 h.

Indications

Swelling and hyperemia of the conjunctiva due to allergic eye diseases or caused by exposure to chemical or physical factors (smoke, dust, chlorinated water, light, cosmetics, contact lenses).

Pharmacological effect

Alpha adrenergic agonist.

Alpha adrenergic agonist, an imidazole derivative, has a vasoconstrictor and anticongestive effect.

The vasoconstrictor effect without secondary reactive hyperemia develops within a few minutes and lasts 4-8 hours.

Special instructions

Use within 28 days after opening the bottle.

Long-term use and overdose should be avoided, especially in children.

If eye disease is not an obstacle to wearing contact lenses, they should be removed before instillation of the drug and installed after about 15 minutes.

Direct contact of eye drops with soft contact lenses should be avoided, given the risk of disruption of their transparency.

If the condition does not improve within 48 hours or if irritation and hyperemia of the eyes persist or increase, you should discontinue the drug and consult a doctor.

If you experience intense pain in the eyes, headache, loss of vision, sudden appearance of “floaters” in front of the eyes, redness of the eyes, pain when exposed to light or double vision, you should immediately consult a doctor.

Impact on the ability to drive vehicles and machinery

If the patient experiences blurred vision after using the drug, it is not recommended to drive a car or engage in activities that require increased attention until it recovers.

Active ingredient

Tetrizoline

Active components

Tetrizoline

Composition

1 ml of solution contains:

Active substance:

Tetrizoline hydrochloride 0.5 mg;

Excipients:

Benzalkonium chloride 0.1 mg,

Disodium edetate dihydrate 1.0 mg,

Sodium chloride 1.80 mg,

Boric acid 12.0 mg,

Sodium tetraborate decahydrate 0.57 mg,

Water for injections up to 1.0 ml.

Pregnancy

The drug may be used during pregnancy and breastfeeding if the expected benefit to the mother outweighs the potential risk to the fetus and child.

Contraindications

Hypersensitivity to the components of the drug, glaucoma, children under 2 years of age, endothelial-epithelial dystrophy of the cornea.

With caution

Arterial hypertension, arrhythmias, aneurysm, thyrotoxicosis, pheochromocytoma, diabetes mellitus, severe organic diseases of the heart and blood vessels (including coronary heart disease); period of treatment with monoamine oxidase inhibitors (MAOIs) and other drugs that increase blood pressure.

Side Effects

Mydriasis, increased intraocular pressure, reactive hyperemia, lacrimation, burning sensation in the eye, pain in the eye, tingling in the eye, blurred vision.

Possible systemic effects: headache, nausea, drowsiness, weakness, tremor, dizziness, insomnia, palpitations, tachycardia, hyperglycemia, increased blood pressure, cardiac dysfunction, allergic reactions.

Interaction

Incompatible with MAO inhibitors, tricyclic antidepressants, maprotiline (possibility of developing a hypertensive crisis), inhalational anesthetics (for example, cyclopropane, halothane and other halogenated anesthetics that can cause ventricular fibrillation).

Overdose

Symptoms:

mydriasis, cyanosis, fever, convulsions, arrhythmias, increased blood pressure, pulmonary edema, dyspnea, cardiac arrest.

Excessive total absorption of imidazole derivatives can lead to depression of the central nervous system, accompanied by drowsiness, hypothermia, bradycardia, collapse, apnea and coma.

The risk of overdose symptoms associated with drug absorption is high in young children, especially if swallowed.

Treatment:

antidote unknown. Activated charcoal, gastric lavage, oxygen inhalation, antipyretic and anti-epileitic drugs are prescribed.

To lower blood pressure – phentolamine 5 mg in saline solution slowly IV or 100 mg orally.

Complete set of goods

Eye drops 0.05%.

10 ml in a colorless glass bottle, sealed with a rubber stopper with a metal cap and tamper evident.

1 bottle, along with a dosing nozzle and instructions for medical use, is placed in a cardboard box.

Functional features

When applied topically, it is practically not absorbed.

Storage conditions

At a temperature of 15 to 25°C, in a place protected from light.

Shelf life

3 years.
Do not use after the expiration date stated on the package.

Manufacturer

Hemomont D.O.O, Montenegro